RANDOMIZED CONTROLLED TRIAL TO ASSESS ACCEPTABILITY OF PHENOBARBITAL FOR CHILDHOOD EPILEPSY IN RURAL INDIA

Citation
Dk. Pal et al., RANDOMIZED CONTROLLED TRIAL TO ASSESS ACCEPTABILITY OF PHENOBARBITAL FOR CHILDHOOD EPILEPSY IN RURAL INDIA, Lancet, 351(9095), 1998, pp. 19-23
Citations number
24
Categorie Soggetti
Medicine, General & Internal
Journal title
LancetACNP
ISSN journal
01406736
Volume
351
Issue
9095
Year of publication
1998
Pages
19 - 23
Database
ISI
SICI code
0140-6736(1998)351:9095<19:RCTTAA>2.0.ZU;2-7
Abstract
Background The use of phenobarbital for childhood epilepsy is controve rsial because of reported behavioural side-effects; however, whether t his research can validly be extrapolated to developing countries is no t clear. We undertook randomised comparison of phenobarbital and pheny toin to assess the acceptability and efficacy of phenobarbital as mono therapy for childhood epilepsy in rural India. Methods Between August, 1995, and February, 1996, 109 unselected children aged 2-18 years wit h partial and generalised tonic-clonic epilepsy were identified by pop ulation screening. 15 families declined to take part. 94 children were randomly allocated treatment with phenobarbital (1.5 mg/kg daily for 2 weeks; maintenance dose 3.0 mg/kg daily; n=47) or phenytoin (2.5 mg/ kg daily then 5.0 mg/kg daily; n=47). Children were followed up for 12 months. The primary outcome measure was the frequency of behavioural side-effects; behaviour was assessed by the Conners parent rating scal e for children aged 6 years and older, and by the preschool behaviour screening questionnaire (BSQ) for those aged 2-5 years, at 12 months o r at withdrawal from treatment. Analysis was by intention to treat. Fi ndings The mean log-transformed scores on the behaviour rating scales did not differ significantly between the phenobarbital and phenytoin g roups (Conners 2.64 [SD 0.71] vs 2.65 [0.89], p=0.97; n=32 in each gro up: BSQ 2.12 [1.31] vs 2.18 [1.02], p=0.94; n=4 vs 3). The odds ratio for behavioural problems (phenobarbital vs phenytoin) was 0.51 (95% CI 0.16-1.59). There was no excess in parental reports of side-effects f or phenobarbital. We found no difference in efficacy between the study drugs (adjusted hazard ratio for time to first seizure from randomisa tion 0.97 [0.28-3.30]). Interpretation This evidence supports the acce ptability of phenobarbital as a first-line drug for childhood epilepsy in rural settings in developing countries.